Capricor Therapeutics (NASDAQ:CAPR) Rating Lowered to “Sell” at Wall Street Zen
Wall Street Zen downgraded shares of Capricor Therapeutics (NASDAQ:CAPR – Free Report) from a hold rating to a sell rating in a research report sent to investors on Thursday. Several other equities analysts also recently issued reports on CAPR. Cantor Fitzgerald reissued an “overweight” rating and issued a $30.00 target price on shares of Capricor […]
Wall Street Zen downgraded shares of Capricor Therapeutics (NASDAQ:CAPR – Free Report) from a hold rating to a sell rating in a research report sent to investors on Thursday. Several other equities analysts also recently issued reports on CAPR. Cantor Fitzgerald reissued an “overweight” rating and issued a $30.00 target price on shares of Capricor […]
